Aktieanalys

Q-linea: Q2 2022, progress with prospects and the US regulatory review - Redeye

Redeye Publicerad: 14 Jul 2022 10:07

In Q2, the first ASTar remains in the stage of expanding the lead prospect pipeline. Actual sales are likely to remain modest during 2022, and Q-linea has pointed towards delivering some 20 systems during 2022, which Thermo Fisher sells as the strategic partner. Q2 sales confirm this level of sales, and total H1 sales in our view, the cost base remains in line with the previous quarter. We do not expect any significant share price reaction from the Q2 results. Our value proposition is a base of SEK 180 (Bull SEK 230 and Bear SEK 90).

Länk till analysen i sin helhet: https://www.redeye.se/research/848517/q-linea-q2-2022-progress-with-prospects-and-the-us-regulatory-review?utm_source=finwire&utm_medium=RSS

Nyheter om Q-Linea

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!